Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | HDAC1 | Q13547 | 4/20 | 0.42 |
| ▸ | KDM1A | O60341 | 3/20 | 0.42 |
| ▸ | TOP1 | P11387 | 2/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | FAAH | O00519 | 1/20 | 0.38 |
| ▸ | ALOX5AP | P20292 | 1/20 | 0.38 |
| ▸ | FEN1 | P39748 | 1/20 | 0.38 |
| ▸ | PPARA | Q07869 | 1/20 | 0.37 |
| ▸ | KIF11 | P52732 | 3/20 | 0.37 |
| ▸ | MAP4K4 | O95819 | 1/20 | 0.36 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.36 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1549277 | 0.85 | IDO1 (0.40) | IDO1TDO2HDAC1KDM1ATOP1 | |
| SCHEMBL1550503 | 0.83 | SCN5A (0.44) | FAAHALOX5APFEN1 | |
| SCHEMBL1549179 | 0.76 | FEN1 (0.46) | IDO1TDO2HDAC1KDM1ATOP1 | |
| SCHEMBL1549536 | 0.76 | KDM1A (0.42) | IDO1TDO2KDM1ATOP1MAOB | |
| SCHEMBL1549624 | 0.75 | ALOX5AP (0.47) | IDO1TDO2HDAC1KDM1AALOX5AP | |
| SCHEMBL1549725 | 0.73 | PPARA (0.50) | IDO1TDO2HDAC1KDM1AMAOB | |
| SCHEMBL30633001 | 0.73 | PPARA (0.50) | IDO1TDO2HDAC1KDM1AMAOB | |
| SCHEMBL2562511 | 0.73 | TDO2 (0.46) | IDO1TDO2HDAC1KDM1ATOP1 | |
| SCHEMBL1993639 | 0.73 | CES2 (0.52) | IDO1 | |
| SCHEMBL4768871 | 0.72 | HDAC1 (0.49) | IDO1TDO2HDAC1KDM1ATOP1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-1875002-B | Phenyl derivatives as PPAR agonists | HOFFMANN LA ROCHE | 2011-08-03 | — | — | CN | disclosed |
| EP-2314576-A1 | Phenyl derivatives as PPAR agonists | F.HOFFMANN-LA ROCHE AG (CH) | 2011-04-27 | — | — | EP | disclosed |
| CN-100509802-C | Heteroaryl deravatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2009-07-08 | — | — | CN | disclosed |
| CN-1878768-A | heteroaryl derivatives as PPAR activators | HOFFMANN LA ROCHE (CH) | 2006-12-13 | — | — | CN | disclosed |
| CN-1875002-A | Phenyl derivatives as PPAR agonists | HOFFMANN LA ROCHE (CH) | 2006-12-06 | — | — | CN | disclosed |
| US-7115611-B2 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-10-03 | — | — | US | disclosed |
| EP-1682508-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| EP-1682535-A1 | HETEROARYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2006-07-26 | — | — | EP | disclosed |
| US-6995263-B2 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. (US) | 2006-02-07 | — | — | US | disclosed |
| WO-2005049606-A1 | HETEROARYL DERIVATIVES AS PPAR ACTIVATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| WO-2005049573-A1 | PHENYL DERIVATIVES AS PPAR AGONISTS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-06-02 | — | — | WO | disclosed |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | HOFFMANN-LA ROCHE INC. | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050096337-A1 | Phenyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | IDO1 3200/4885TDO2 3533/4885HDAC1 1082/4885 |
| US-20050096353-A1 | Indolyl and dihydroindolyl derivatives, their manufacture and use as pharmaceutical agents | PPARD, PPARA, PPARG | IDO1 321/4885TDO2 1001/4885HDAC1 1602/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.